

PRIOR AUTHORIZATION REQUEST FORM

Individual and Family Plans

Sofosbuvir-Velpatasvir and Epclusa

Fax back to: (833) 605-4407

Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:
Member Number:	Fax: Phone:
Date of Birth:	Office Contact:
Line of Business: 🛛 Exchange - PA	NPI: State Lic ID:
Address:	Address:
City, State ZIP:	City, State ZIP:
Primary Phone:	Specialty/facility name (if applicable):

<u>REQUEST FOR EXPEDITED REVIEW</u>: By checking this box and signing below, I certify that the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function.

Drug Name:	
Strength:	
Directions / SIG:	

Please attach any pertinent medical history including labs and information for this member that may support approval. Please answer the following questions and sign.		
Q1. Is the member prescribed a dose and duration of therapy that are consistent with FDA- approved package labeling, current AASLD-IDSA HCV guidance, nationally recognized compendia, or peer-reviewed medical literature?		
□ Yes	□ No	
Q2. Does the member have a contraindication to the prescribed drug?		
□ Yes	□ No	
Q3. Does the member have the diagnosis of chronic HCV?		
□ Yes	□ No	
Q4. Does the member have documentation of HCV treatment history and documentation of previous HCV treatment regimens if the member has received prior HCV treatment?		
□ Yes	□ No	
Q5. Does the member have documented results of the following? a. HCV genotype (All)		

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



PRIOR AUTHORIZATION REQUEST FORM

Individual and Family Plans

Sofosbuvir-Velpatasvir and Epclusa

Fax back to: (833) 605-4407 Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:	
 b. Quantitative HCV RNA c. Complete blood count (CBC) d. International normalized ratio (INR) e. Hepatic function panel (albumin, total and direct bilirubin, alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase levels) f. Metavir fibrosis score documented by a recent noninvasive test (e.g., blood test or imaging, a Fibroscan, or findings on physical examination) g. Hepatitis B surface antigen (HBsAg) h. HIV antigen/antibody test 		
□ Yes	□ No	
Q6. Is the member an HCV-uninfected transplant recipient receiving organ from HCV-viremic doner?		
□ Yes	□ No	
Q7. Has the prescriber provided chart notes (transplantation) and labs (quantitative HCV RNA) from the donor?		
□ Yes	□ No	
Q8. Additional Information:		

Prescriber Signature

Date

v2025

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document